1. Prognostic Factors of Chronic Graft-versus-Host Disease Following Allogeneic Peripheral Blood Stem Cell Transplantation: The National Institutes Health Scale Plus the Type of Onset Can Predict Survival Rates and the Duration of Immunosuppressive Therapy 
José A. Pérez-Simón, Cristina Encinas, Fernando Silva, Maria José Arcos, María Díez-Campelo, Fermín M. Sánchez-Guijo, Enrique Colado, Jesús Martín, Lourdes Vazquez, Consuelo del Cañizo, Dolores Caballero, Jesús San Miguel 
Biology of Blood and Marrow Transplantation 
Volume 14, Issue 10, Pages (October 2008)
DOI: /j.bbmt
Copyright © 2008 American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1
Cumulative incidence of cGVHD according to standard criteria (A) and to NIH-based criteria (B).
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2008 American Society for Blood and Marrow Transplantation Terms and Conditions

3. Figure 2
Relapse of cGVHD in patients who responded to first-line treatment (A) and according to the NIH scale (B).
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2008 American Society for Blood and Marrow Transplantation Terms and Conditions

4. Figure 3 Probability of being off immunosuppression at last follow-up.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2008 American Society for Blood and Marrow Transplantation Terms and Conditions

5. Figure 4
OS and EFS for the whole series of patients (A); OS in patients with de novo, quiescent, or progressive-onset cGVHD (B); and OS in patients with mild, moderate, or severe cGVHD (C).
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2008 American Society for Blood and Marrow Transplantation Terms and Conditions

6. Figure 5
OS in patients with cGVHD according to NIH score plus type of onset. OS, depending on grade of severity according to the NIH scoring system plus type of onset, was 82% for patients with mild cGVHD regardless of the type of onset and patients with moderate cGVHD with de novo onset, 70% for patients with moderate cGVHD and quiescent or progressive onset, 50% for patients with severe cGVHD and de novo onset, and 25% for patients with severe cGVHD and quiescent or progressive onset.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2008 American Society for Blood and Marrow Transplantation Terms and Conditions